Tag:
AVEO Pharmaceuticals
Latest Headlines
Latest Headlines
UPDATED: ASCO abstracts reveal added appeal for key cancer drug prospects
The avalanche of ASCO abstracts last night triggered a flurry of news reports about the most notable new data on experimental therapies to be revealed ahead of next month's big meeting in Chicago.
Aveo Pharma flunks Phase II lung cancer study
Aveo's share price slid a modest 30 cents, or 2.53%, to $11.77, as of 10:30 a.m. ET Wednesday.
Aveo on a hiring spree as it preps for the launch of tivozanib
The fast-growing developer tells The Boston Globe that it plans to hire 120 new staffers this year in preparation for the likely upcoming launch of tivozanib.
UPDATED: Aveo shares sink on weak PhIII face-off with Nexavar
Aiming at a regulatory filing for the experimental kidney cancer drug tivozanib later this year, Aveo Pharmaceuticals ( $AVEO ) unveiled a slate of late-stage data this morning designed to help build
Key R&D programs moving biotech stocks
TheSteet's Adam Feuerstein takes at look today at some of the most actively traded biotech stocks today, highlighting a number of companies such as AVEO Pharmaceuticals ($AVEO), Targacept ($TRGT) and
AVEO garners $100M from stock offering
AVEO Pharmaceuticals says it will net slightly more than $100 million on its sale of 5.75 million discounted shares, much of which will be used for its ambitious R&D plans. The developer recently
Booming AVEO inks $555M antibody deal with J&J
With its lead cancer drug forging ahead in Phase III and a major development deal with Astellas helping pay for a burgeoning staff, Cambridge, MA-based AVEO announced a new development pact with
Outgoing Genzyme CEO Termeer hops on to AVEO board
Henri Termeer ( photo ) is leaving the newly acquired Genzyme with a severance deal worth potentially more than $200 million, but he'll be keeping his finger in the biotech game as a new director of
Aveo inks $1.4B cancer drug deal, blueprints rapid expansion
Aveo Pharmaceuticals ( $AVEO ) has landed a rich, $1.4 billion development and commercialization pact with Astellas for its late-stage VEGF inhibitor tivozanib. Now in a Phase III head-to-head study
Merck returns drug rights to AVEO
Portfolio prioritization has caused Merck to return AV-299, an anti-hepatocyte growth factor antibody drug, to AVEO Pharmaceuticals. In June the developer initiated a Phase II trial of the drug,
